3P Biopharmaceuticals appoints Iker Portugal as Chief Financial Officer

20 July, 2020 | General

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics incorporates a new member to the management team and appoints Iker Portugal as Chief Financial Officer. Iker Portugal is an experienced financial manager and joins 3P Biopharmaceuticals with the aim of boosting the company´s growth […]

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

22 June, 2020 | General

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, together with Toleranzia, a Swedish Biotech company, have initiated a collaboration on innovative treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG). 3P Biopharmaceuticals and Toleranziabegan their partnership in 2019, when 3P Biopharmaceuticals was selected to […]

3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research

24 April, 2020 | General

CIR certificate is extended for a four-year period between 2020-2024 3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024. The CIR ”Credit Impôt Recherche” or French Research Tax Credit is a corporate […]

STATEMENT: 3P Biopharmaceuticals shows its commitment against Covid-19

25 March, 2020 | General

We are living in difficult times due to the COVID19 pandemic, and it is in these times of serious difficulty that 3P Biopharmaceuticals shows its maximum commitment to its employees and to society. Therefore, 3P Biopharmaceuticals makes its capabilities and knowledge available to the Spanish Health Authorities as well as companies in the pharmaceutical and […]

Day of Women and Girls in Science

3P Biopharmaceuticals joins International Day of Women and Girls in Science

11 February, 2020 | General

At 3P Biopharmaceuticals we celebrate the International Day of Women and Girls in Science, and we want to do so by appreciating and thanking each of the women that forms part of the 3P team. Science and innovation do not understand gender and at 3P Biopharmaceuticals it is a real fact. Out of the 270 […]

vaccine against equine strangles Strangvac

Validation batches of the vaccine against equine strangles Strangvac® is completed

28 January, 2020 | General

3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics has, together with the Swedish biotechnology company Intervacc AB and LIOF-Pharma (previously Praxis Pharmaceutical), completed the manufacturing process for the vaccine against equine strangles called Strangvac®. The validation production batches required for the forthcoming registration application to the European Medicines […]

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

2 January, 2020 | General

3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use. 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and Viscofan BioEngineering, the Business Unit within the Viscofan Group), go one step further in an innovative cell therapy product. […]

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

28 November, 2019 | General

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, the UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment. 3P Biopharmaceuticals and In3Bio began their partnership in early 2019 with 3P Biopharmaceuticals being selected to […]

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

21 October, 2019 | General

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and the American biotech company, Zhittya Genesis Medicine (Zhittya), have successfully accomplished a tech transfer. 3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer […]

3P Biopharmaceuticals receives FDA approval

18 September, 2019 | General

The FDA classified 3P facilities as acceptable for the manufacture of the target molecule, and appropriate for its commercialization in the US market, once the product is authorized. 3P Biopharmaceuticals a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection […]